

1 **Draft – Minutes**
2 **Toxicology Subcommittee of the Scientific Advisory Committee Meeting**
3 **October 11, 2017**
4 **Department of Forensic Science, Central Laboratory, Classroom 1**
5
6

7 **Subcommittee Members Present**
8

9 Maureen C. Bottrell
10 Leslie E. Edinboro, Ph.D., Chair
11 Barry S. Levine, Ph.D.
12 Richard P. Meyers
13 Jami J. St. Clair
14

15 **Committee Members Present**
16

17 Linda C. Jackson
18

19 **Subcommittee Members Absent**
20

21 None
22

23 **Staff Members Present**
24

25 David A. Barron, Ph.D., Deputy Director
26 Amy M. Curtis, Department Counsel
27 James W. Hutchings, Ph.D., Toxicology Program Manager
28 Alka B. Lohmann, Technical Services Director
29 Rebecca L. Wagner, Ph.D., Research Analyst
30 Carisa M. Studer, Legal Assistant
31

32 **Call to Order**
33

34 Leslie Edinboro, Ph.D., the Chair of the Scientific Advisory Committee's Toxicology
35 Subcommittee, called the meeting to order at 9:01 a.m.
36

37 **Adoption of the Agenda**
38

39 Dr. Edinboro asked if there were any additions or changes to the draft agenda for the meeting.
40 Ms. St. Clair made a motion to adopt the agenda, the motion was seconded by Dr. Levine and
41 adopted by unanimous vote of the Subcommittee.
42

43 **Discussion of the OpiCoc Protein Precipitation Validation**
44

44 The members of the Subcommittee were provided a copy of the Virginia Department of Forensic
45 Science's (DFS or the Department) OpiCoc Protein Precipitation Validation in advance of the
46 meeting. Dr. Edinboro led a discussion between the Subcommittee members and DFS staff

47 regarding the validation. Dr. Hutchings and Dr. Wagner answered the Subcommittee members'
48 questions regarding the validation. Dr. Wagner explained to the Subcommittee how the
49 Department conducts a validation, which includes a validation plan, summary, and the regional
50 laboratories conducting appropriate verifications.

51
52 Subcommittee members provided comments and made suggestions for DFS to consider for the
53 OpiCoc Protein Precipitation Validation. The Subcommittee recommended a formal quantitative
54 validation procedure be published. Specifically, for the OpiCoc validation, additional
55 experiments/items were suggested for consideration including significant figure consistency, and
56 testing the analytical measurement range to compare the new to the previous method. The review
57 of the OpiCoc Protein Precipitation Validation was closed.

58
59 **Discussion of the LCMSMS Evaluation of Opiate Metabolite Interferences**
60 The members of the Subcommittee were provided a copy of the Department's LCMSMS
61 Evaluation of Opiate Metabolite Interferences in advance of the meeting. Dr. Edinboro led a
62 discussion between the Subcommittee members and DFS staff regarding the evaluation. The
63 Subcommittee noted to staff that naloxone should be added to the evaluation and recommended
64 that DFS test naloxone at clinically significant concentrations. With that, the Subcommittee
65 recommended that the review of the LCMSMS Evaluation of Opiate Metabolite Interferences be
66 closed.

67
68 **Public Comment**
69
70 None.

71
72 **Adjournment**
73
74 Dr. Edinboro made a motion to adjourn the meeting of the Scientific Advisory Committee, which
75 was seconded by Jami St. Clair and passed by unanimous vote.

76
77 The meeting adjourned at 9:32 a.m.